---
title: Long-term Follow-up from A041202 Shows Continued Efficacy of Ibrutinib Regimens
  for Older Adults with CLL
date: '2024-01-12'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38215395/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240113170706&v=2.18.0
source: Blood
description: A041202 (NCT01886872) is a phase 3 study comparing bendamustine plus
  rituximab (BR) with ibrutinib and the combination of ibrutinib plus rituximab (IR)
  in previously untreated older patients with CLL. Initial results showed that ibrutinib-containing
  regimens had superior PFS and rituximab did not add additional benefit. Here we
  present an updated analysis. With median follow-up of 55 months, median PFS was
  44 months (95% CI 38-54) for BR and not yet reached in either ibrutinib-containing
  ...
disable_comments: true
---
A041202 (NCT01886872) is a phase 3 study comparing bendamustine plus rituximab (BR) with ibrutinib and the combination of ibrutinib plus rituximab (IR) in previously untreated older patients with CLL. Initial results showed that ibrutinib-containing regimens had superior PFS and rituximab did not add additional benefit. Here we present an updated analysis. With median follow-up of 55 months, median PFS was 44 months (95% CI 38-54) for BR and not yet reached in either ibrutinib-containing ...